Literature DB >> 6222111

Immunologic effects of interleukin 2 in primary immunodeficiency diseases.

N Flomenberg, K Welte, R Mertelsmann, N Kernan, N Ciobanu, S Venuta, S Feldman, G Kruger, D Kirkpatrick, B Dupont, R O'Reilly.   

Abstract

Five children with primary deficiencies of T cell function were studied to assess the effects of highly purified exogenous Interleukin 2 (IL 2) on their in vitro T cell responses. The lymphocytes from one child with Nezelof's T cell deficiency demonstrated absence of endogenous IL 2 production and improved proliferative responses to mitogen or alloantigen in the presence of exogenous IL 2. Moreover, during in vitro mixed lymphocyte culture in the presence of exogenous IL 2, his lymphocytes were able to develop into cytotoxic effector cells. A second child with Nezelof's syndrome demonstrated a different type of defect. The lymphocytes from this child had less impairment of endogenous IL 2 production. Although IL 2 increased the proliferation of his cells in response to PHA, similar augmentation was not seen after stimulation with OKT3 or alloantigen. In cell-mediated cytotoxicity assays, after mixed lymphocyte culture, natural killer-like activity was strongly boosted in the cultures that contained IL 2, but T cell-mediated cytotoxicity was not. The lymphocytes from three patients with severe combined immunodeficiency did not show improved proliferative responses in the presence of IL 2. Thus, only one of the five patients demonstrated the combination of defective endogenous IL 2 production, but preservation of the ability to respond appropriately to exogenous IL 2. This child may therefore have suffered from a T cell defect pathophysiologically similar to that seen in nude or aged mice.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222111

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  The interleukins in acquired disease.

Authors:  M Malkovský; P M Sondel; W Strober; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

2.  Recombinant interleukin 2 therapy in severe combined immunodeficiency disease.

Authors:  R Pahwa; T Chatila; S Pahwa; C Paradise; N K Day; R Geha; S A Schwartz; H Slade; N Oyaizu; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

3.  Defective expression of T cell-associated glycoprotein in severe combined immunodeficiency.

Authors:  L K Jung; S M Fu; T Hara; N Kapoor; R A Good
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

4.  In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).

Authors:  N Saijo; A Ozaki; H Nakano; M Sakurai; H Takahashi; Y Sasaki; A Hoshi
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 5.  Lymphocyte proliferation, lymphokine production, and lymphocyte receptors in ageing and various clinical conditions.

Authors:  A L de Weck; F Kristensen; F Joncourt; F Bettens; C Walker; Y Wang
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Recombinant human interleukin-2 reverses in vitro-deficient cell-mediated immune responses to tuberculin purified protein derivative by lymphocytes of tuberculous patients.

Authors:  H Shiratsuchi; Y Okuda; I Tsuyuguchi
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

7.  In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice.

Authors:  V Colizzi
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

8.  Antibodies of predetermined specificity against chemically synthesized peptides of human interleukin 2.

Authors:  A Altman; J M Cardenas; R A Houghten; F J Dixon; A N Theofilopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

Review 9.  Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient.

Authors:  S Doi; O Saiki; T Hara; T Sugita; K Ha-Kawa; T Tanaka; H Hara; S Negoro; H Yabuuchi; S Kishimoto
Journal:  Eur J Pediatr       Date:  1989-06       Impact factor: 3.183

10.  Impaired production of interleukin-2 after surgery.

Authors:  T Akiyoshi; F Koba; S Arinaga; S Miyazaki; T Wada; H Tsuji
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.